Swathi Balaji1, Maria LeSaint1, Sukanta S Bhattacharya1, Chad Moles1, Yashu Dhamija1, Mykia Kidd1, Louis D Le1, Alice King1, Aimen Shaaban1, Timothy M Crombleholme2, Paul Bollyky3, Sundeep G Keswani4. 1. Division of Pediatric, General, Thoracic and Fetal Surgery, Laboratory for Regenerative Wound Healing, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 2. Center for Children's Surgery, Children's Hospital Colorado and the University of Colorado, School of Medicine, Aurora, Colorado. 3. Department of Medicine, Stanford University, Palo Alto, California. 4. Division of Pediatric, General, Thoracic and Fetal Surgery, Laboratory for Regenerative Wound Healing, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. Electronic address: sundeep.keswani@cchmc.org.
Abstract
BACKGROUND: Chronic wounds are characterized by a wound healing and neovascularization deficit. Strategies to increase neovascularization can significantly improve chronic wound healing. Insulin-like growth factor (IGF)-1 is reported to be a keratinocyte mitogen and is believed to induce angiogenesis via a vascular endothelial growth factor (VEGF)-dependent pathway. Using a novel ex vivo human dermal wound model and a diabetic-impaired wound healing murine model, we hypothesized that adenoviral overexpression of IGF-1 (Ad-IGF-1) will enhance wound healing and induce angiogenesis through a VEGF-dependent pathway. METHODS: Ex vivo: 6-mm full-thickness punch biopsies were obtained from normal human skin, and 3-mm full-thickness wounds were created at the center. Skin explants were maintained at air liquid interface. Db/db murine model: 8-mm full-thickness dorsal wounds in diabetic (db/db) mice were created. Treatment groups in both human ex vivo and in vivo db/db wound models include 1×10(8) particle forming units of Ad-IGF-1 or Ad-LacZ, and phosphate buffered saline (n=4-5/group). Cytotoxicity (lactate dehydrogenase) was quantified at days 3, 5, and 7 for the human ex vivo wound model. Epithelial gap closure (hematoxylin and eosin; Trichrome), VEGF expression (enzyme-linked immunosorbent assay), and capillary density (CD 31+CAPS/HPF) were analyzed at day 7. RESULTS: In the human ex vivo organ culture, the adenoviral vectors did not demonstrate any significant difference in cytotoxicity compared with phosphate buffered saline. Ad-IGF-1 overexpression significantly increases basal keratinocyte migration, with no significant effect on epithelial gap closure. There was a significant increase in capillary density in the Ad-IGF-1 wounds. However, there was no effect on VEGF levels in Ad-IGF-1 samples compared with controls. In db/db wounds, Ad-IGF-1 overexpression significantly improves epithelial gap closure and granulation tissue with a dense cellular infiltrate compared with controls. Ad-IGF-1 also increases capillary density, again with no significant difference in VEGF levels in the wounds compared with control treatments. CONCLUSIONS: In two different models, our data demonstrate that adenoviral-mediated gene transfer of IGF-1 results in enhanced wound healing and induces angiogenesis via a VEGF-independent pathway. Understanding the underlying mechanisms of IGF-1 effects on angiogenesis may help produce novel therapeutics for chronic wounds or diseases characterized by a deficit in neovascularization.
BACKGROUND: Chronic wounds are characterized by a wound healing and neovascularization deficit. Strategies to increase neovascularization can significantly improve chronic wound healing. Insulin-like growth factor (IGF)-1 is reported to be a keratinocyte mitogen and is believed to induce angiogenesis via a vascular endothelial growth factor (VEGF)-dependent pathway. Using a novel ex vivo human dermal wound model and a diabetic-impaired wound healing murine model, we hypothesized that adenoviral overexpression of IGF-1 (Ad-IGF-1) will enhance wound healing and induce angiogenesis through a VEGF-dependent pathway. METHODS: Ex vivo: 6-mm full-thickness punch biopsies were obtained from normal human skin, and 3-mm full-thickness wounds were created at the center. Skin explants were maintained at air liquid interface. Db/db murine model: 8-mm full-thickness dorsal wounds in diabetic (db/db) mice were created. Treatment groups in both human ex vivo and in vivo db/db wound models include 1×10(8) particle forming units of Ad-IGF-1 or Ad-LacZ, and phosphate buffered saline (n=4-5/group). Cytotoxicity (lactate dehydrogenase) was quantified at days 3, 5, and 7 for the human ex vivo wound model. Epithelial gap closure (hematoxylin and eosin; Trichrome), VEGF expression (enzyme-linked immunosorbent assay), and capillary density (CD 31+CAPS/HPF) were analyzed at day 7. RESULTS: In the human ex vivo organ culture, the adenoviral vectors did not demonstrate any significant difference in cytotoxicity compared with phosphate buffered saline. Ad-IGF-1 overexpression significantly increases basal keratinocyte migration, with no significant effect on epithelial gap closure. There was a significant increase in capillary density in the Ad-IGF-1 wounds. However, there was no effect on VEGF levels in Ad-IGF-1 samples compared with controls. In db/db wounds, Ad-IGF-1 overexpression significantly improves epithelial gap closure and granulation tissue with a dense cellular infiltrate compared with controls. Ad-IGF-1 also increases capillary density, again with no significant difference in VEGF levels in the wounds compared with control treatments. CONCLUSIONS: In two different models, our data demonstrate that adenoviral-mediated gene transfer of IGF-1 results in enhanced wound healing and induces angiogenesis via a VEGF-independent pathway. Understanding the underlying mechanisms of IGF-1 effects on angiogenesis may help produce novel therapeutics for chronic wounds or diseases characterized by a deficit in neovascularization.
Authors: Swathi Balaji; Sachin S Vaikunth; Stephanie A Lang; Abdul Q Sheikh; Foong Y Lim; Timothy M Crombleholme; Daria A Narmoneva Journal: Wound Repair Regen Date: 2011-12-08 Impact factor: 3.617
Authors: Tobias Hirsch; Sebastian von Peter; Grzegorz Dubin; Dominik Mittler; Frank Jacobsen; Markus Lehnhardt; Elof Eriksson; Hans-Ulrich Steinau; Lars Steinstraesser Journal: Mol Med Date: 2006 Sep-Oct Impact factor: 6.354
Authors: M Lange; J Thulesen; U Feldt-Rasmussen; N E Skakkebaek; N Vahl; J O Jørgensen; J S Christiansen; S S Poulsen; S B Sneppen; A Juul Journal: Eur J Endocrinol Date: 2001-08 Impact factor: 6.664
Authors: Chandan K Sen; Gayle M Gordillo; Sashwati Roy; Robert Kirsner; Lynn Lambert; Thomas K Hunt; Finn Gottrup; Geoffrey C Gurtner; Michael T Longaker Journal: Wound Repair Regen Date: 2009 Nov-Dec Impact factor: 3.617
Authors: Daniela Fernanda Dezotti Silva; Lucas de Oliveira Fujii; Gabriela Bortolança Chiarotto; Camila Andrea de Oliveira; Thiago Antônio Moretti de Andrade; Alexandre Leite Rodrigues de Oliveira; Marcelo Augusto Marretto Esquisatto; Fernanda Aparecida Sampaio Mendonça; Gláucia Maria Tech Dos Santos; Andrea Aparecida de Aro Journal: Mol Biol Rep Date: 2021-01-21 Impact factor: 2.316
Authors: Johanna M Sweere; Heather Ishak; Vivekananda Sunkari; Michelle S Bach; Robert Manasherob; Koshika Yadava; Shannon M Ruppert; Chandan K Sen; Swathi Balaji; Sundeep G Keswani; Patrick R Secor; Paul L Bollyky Journal: Adv Wound Care (New Rochelle) Date: 2019-12-18 Impact factor: 4.730
Authors: Kathryn O'Brien; Ayesha Bhatia; Fred Tsen; Mei Chen; Alex K Wong; David T Woodley; Wei Li Journal: PLoS One Date: 2014-12-02 Impact factor: 3.240